PRA, AMR collaborate on vaccine development
PRA’s vaccine experience includes phase I-phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. PRA has provided clinical development support for 10 approved vaccines over the past five years. Additionally, PRA supports four of the five top vaccine manufacturers.
AMR provides clinical study services across a broad range of therapeutic areas and has a breadth of vaccine trial experience for a variety of vaccine indications, including several bioterrorism-related government sponsored programs. Combining AMR and PRA expertise will allow for successful support of small to mid-size vaccine trials and AMR’s 98% subject retention rate will help sponsors meet or exceed enrollment timelines.
The vaccine market traditionally has been pediatric, but the adult vaccine market continues to grow and is expected to nearly double by 2020. Many of the vaccines under development in the adult market segment focus on infectious diseases such as avian flu, malaria and hepatitis, as well as cancer treatment and prevention.
The collaboration between PRA and AMR will facilitate identification of appropriate patient populations for vaccine studies, which could reduce development times and help bring much needed vaccines to market sooner.